Company intelligence / Profile preview

HuntX Pharma

Grenoble, Auvergne-Rhône-Alpes, Francehuntxpharma.com ↗

Ownership: Private
Development stage: Other

Overview

HuntX Pharma has demonstrated in preclinical in vivo studies that its lead compound, HX127, protects the brain from degeneration and reverses symptoms associated with Huntington's disease. The company is finalizing preclinical studies with plans to initiate regulatory animal studies and launch a Phase 1 clinical trial by 2026. Their approach has shown both protective and curative effects in several models of neurodegenerative diseases linked to axonal transport defects.[4][1]

Therapeutic areas: Neurology
Modalities: Small moleculeOral small molecule
Industry: Biotech

Drug pipeline

1 asset

HX127

Preclinical

Partnerships

SATT Linksium (maturation/incubation support and shareholder)

Beyond the preview

Go deeper on HuntX Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HuntX Pharma.

Explore the full profile